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Abstract
Background: Recent literature has distinguished the negative symptoms associated with a diminished capacity to
experience (apathy, anhedonia) from symptoms associated with a limited capacity for expression (emotional
blunting, alogia). The apathy-anhedonia syndrome tends to be associated with a poorer prognosis than the
symptoms related to diminished expression. The efficacy of drug-based treatments and psychological interventions
for these symptoms in schizophrenia remains limited. There is a clear clinical need for new treatments.
Methods: This pilot study tested the feasibility of a program to reduce anhedonia and apathy in schizophrenia and
assessed its impact on 37 participants meeting the ICD-10 criteria for schizophrenia or schizoaffective disorders.
Participants were pre- and post-tested using the Scale for the Assessment of Negative Symptoms (SANS) and the
Calgary Depression Scale for Schizophrenia (CDSS). They took part in eight sessions of the Positive Emotions
Program for Schizophrenia (PEPS)—an intervention that teaches participants skills to help overcome defeatist
thinking and to increase the anticipation and maintenance of positive emotions.
Results: Thirty-one participants completed the program; those who dropped out did not differ from completers.
Participation in the program was accompanied by statistically significant reductions in the total scores for Avolition-Apathy
and Anhedonia-Asociality on the SANS, with moderate effect sizes. Furthermore, there was a statistically significant reduction
of depression on the CDSS, with a large effect size. Emotional blunting and alogia remain stable during the intervention.
Discussion: Findings indicate that PEPS is both a feasible intervention and is associated with an apparently specific
reduction of anhedonia and apathy. However, these findings are limited by the absence of control group and the fact
that the rater was not blind to the treatment objectives.
Conclusions: PEPS is a promising intervention to improve anhedonia and apathy which need to be tested further in a
controlled study.
Trial registration number: ISRCTN registry ISRCTN74048461, registered 18 may 2015
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Background
Anhedonia—the difficulty of anticipating or experiencing
pleasure—is a particularly challenging negative symptom
of schizophrenia. Anhedonia is often associated with ap-
athy and social withdrawal, and is one of schizophrenia’s
characteristic features. The literature distinguishes the
negative symptoms associated with a diminished cap-
acity to experience (anhedonia, asociality, and avolition)
from those which are associated with a limited capacity
for expression (emotional blunting, alogia) [1, 2]. These
negative symptoms can significantly contribute to a de-
crease in social [3] and professional [4] functioning, and
they are linked to a lower quality of life [5]. The syn-
drome of apathy-anhedonia tends to be associated with
a poorer prognosis than the symptoms related to dimin-
ished expression, which suggests that it is the more
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severe facet of the psychopathology [6]. The efficacy of
drug-based treatments and psychological interventions re-
mains limited [7, 8], and there is a clear clinical need for
new treatments for negative symptoms [9]. In order to im-
prove social functioning, experts strongly recommend
combining psychosocial interventions with pharmaco-
logical treatments [10]. Existing psychosocial treat-
ments, however, are not specific enough, and often
only improve negative symptoms indirectly [11]. Inter-
ventions which challenge defeatist thinking do play a
beneficial role [12, 13].
Several studies have underlined that individuals with
schizophrenia are less active or less involved in enjoyable
and positive activities than non-sufferers. Laboratory
studies measuring what sufferers actually experience
when confronted with pleasurable stimuli, have shown
however, that patients do not experience less pleasure
than control subjects [14]. This paradox is explained by
the fact that individuals with schizophrenia experience a
deficit of anticipatory pleasure rather than in-the-
moment pleasure [15–17]. Together, patients may have
an impaired ability to envision the future and this diffi-
culty is associated with apathy [18]. These results sug-
gest that within the syndrome of diminished capacity to
experience, apathy and anhedonia, might be the results
of the same underlying process: that is, a diminished
capacity to anticipate a particular experience or the
achievement of a pleasurable goal [19] or a motivational
impairment [20]. Patients also reported lower levels of
pleasure in savoring past, present, and future events than
did normal controls, and stated that they had low expec-
tations of their self-efficacy [21]. Savoring is the capacity
to wait for, appreciate, and enhance a positive experience
[22]. Individuals with schizophrenia also manifest a
lesser ability to maintain positive emotions [23–25]. The
facial expression of emotions can play a causal role in
the subjective experience of those emotions [26]. Even
though observable outward signs of emotional expres-
sion are lessened in schizophrenia, studies indicate that
sufferers continue to display very subtle facial muscle
movements (as measured by electromyogram) that are
similar to and in accordance with their responses [27].
These data highlight target deficits in the temporal
experience of pleasure, anticipating, maintaining and
expressing positive emotions. Strauss [28] suggested
maximizing positive emotional experiences by using
techniques developed in the field of affective science
[22, 26] to increase the frequency and duration of
positive emotional experiences. Five techniques have
been found to specifically and reliably increase the
frequency, intensity, and duration of positive emotions.
They include anticipating the enjoyment; behavioral dis-
play (expressing emotions via nonverbal behaviors); being
‘in the moment’ (directing controlled attention toward
positive experiences when they occur—savoring);
communicating and celebrating positive experiences
with others; and recalling previously pleasurable
events.
Cognitive behavior therapy (CBT) for psychosis or
metacognitive training (MCT) have been shown to be ef-
fective on negative symptoms or self-esteem [29, 30].
However very few studies on schizophrenia have specif-
ically targeted anhedonia and apathy. An open pilot trial
using Loving Kindness Meditation, as a method of in-
creasing positive emotions, led to an improvement in
negative symptoms [31]. Another pilot study [32]
showed that training in anticipatory pleasure led to an
improvement of anhedonia and an increase in activity.
PEPS (Positive Emotions Program for Schizophrenia) is
a new intervention meant to improve apathy and an-
hedonia by increasing cognitive control of positive
emotions, including the anticipation and maintenance
of those emotions [33,34]. Despite the similar format
of MCT and PEPS, MCT focuses mainly on delusional
symptoms whilst PEPS focuses more on negative
symptoms.
This pilot study’s goal was to test the program’s
feasibility and its effects on individuals with a
schizophrenia-spectrum disorder who presented symp-
toms of anhedonia. Our hypothesis was that eight sessions
of PEPS would reduce anhedonia and apathy, as measured
using the Scale for the Assessment of Negative Symptoms
(SANS).
Methods
This pilot study uses an open pre-post comparison
within subject design.
Participants and inclusion criteria
Participants were recruited at three social and nursing
homes, in Lausanne, Rolle and Marsens—towns in
French-speaking Switzerland. The inclusion criteria
were:
 Fulfilling the ICD-10 criteria for a diagnosis of
schizophrenia or a schizoaffective disorder.
 Presenting a score of at least 2 on the overall SANS
anhedonia scale.
 Being aged between 18 and 65 years old.
 Being able to read and understand French.
 Demonstrating capacity for consent according to
the San Diego Brief Assessment of Capacity to
Consent [35]. This tool measures a patient's
understanding of an information sheet. If the
potential participant is unable to respond
correctly to the questions asked after reading the
sheet, the patient is excluded. The procedure can
be conducted a maximum of twice.
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Measures
The following data and scales were used in pre- and
post-tests as part of standardized interviews with a
psychologist trained in their administration. The average
time needed to complete the scales with the participants
was one hour.
▪ Collection of socio-demographic and clinical data:
age, sex, psychiatric diagnosis, duration of illness, living
arrangements (e.g., nursing home, with family), treat-
ment, etc.
▪ Scale for the Assessment of Negative Symptoms
(SANS) [36] : this scale measures schizophrenia’s deficit
symptoms within the framework of schizophrenic
disorders. It comprises of 25 items, scored from 0 to 5.
A definition of each item, including examples,
facilitates a better understanding of scale’s content. The
rating system is ordinal, from 0 (absent) to 5 (severe).
The 25 items are grouped into five components: (1)
withdrawal or emotional poverty; (2) alogia (lack of
speech); (3) avolition and apathy (lack of energy, lack of
initiative); (4) anhedonia and social withdrawal (loss of
interests); (5) attention. A score is given to each
component. Results can be expressed in several forms:
an overall score (0 to 125), the sub-scores of each com-
ponent, sum of all sub-scores or sum of the five items
of the overall evaluation. The scale was translated into
French with acceptable validity [37, 38].
▪ The Calgary Depression Scale for Schizophrenia
(CDSS) [39] includes nine items: depression,
hopelessness, self-depreciation, guilty ideas of reference,
pathological guilt, morning depression, early wakening,
suicide and observed depression. This scale has been
validated in French [40].
▪ The Savoring Belief Inventory (SBI) is a scale for
measuring beliefs about one's capacity for savoring
things. It is a 24-item scale including a positive scale
(12 items) and a negative scale (12 items). The scale
has good validity and a high test-re-test reliability [41].
The scale measures a person's thinking regarding their
capacity to savor positive experiences, in terms of past
experiences, current experiences, and future
anticipation.
Intervention
PEPS is an intervention meant to reduce anhedonia and
apathy. The program teaches skills to help overcome de-
featist thinking and to increase the anticipation and
maintenance of positive emotions. PEPS involves 8 one-
hour group sessions, administered using visual and
audio materials and presented as PowerPoint presenta-
tion slides projected onto a screen. The program was
conceived by Jérôme Favrod and Alexandra Nguyen. The
future group leaders participated in a training day and
worked through all of the program's exercises together.
The trainee group leaders included four nurses, two
nursing assistants and four social workers—eight men
and two women. Their mean age was 34.10 years (S.D.
7.45) and they had been working for an average of
9.40 years (SD 5.78) since their receiving their profes-
sional diplomas.
Description of PEPS
A typical PEPS’s session includes the following steps.
The first part of the session begins with a welcome,
followed by a five minute relaxation-meditation exercise.
The second part of the session starts with the group
leaders going over the homework task that was given
during the previous session. The session continues with
an exercise in challenging specific defeatist thoughts
which are presented using the program’s two fictitious
heroes—Jill and Jack. Jill, for example, expresses the de-
featist thinking: “I can’t relax; I’m useless.” The partici-
pant’s role is to challenge her belief, first by assigning
different reasons to Jill’s difficulty to relax. They learn to
find reasons which might be linked to the program’s
hero, the other people or to Jill’s environment. They sub-
sequently try to develop an alternative, a more positive
way of thinking. Modifying defeatist thinking appear to
be an essential supplementary ingredient to treat
negative symptom because of repeated failures in pa-
tients account [13, 42, 43]. Following this introduc-
tion, and according to the session theme, participants
learn and practice a new skill to improve their antici-
pation or maintenance of pleasure. The session ends
with the setting of the homework task that the partic-
ipants must accomplish for the next session.
Key targets
The skills taught are: savoring a present or past pleasant
experience, expressing emotions by increasing behavioral
expression, making the most of or capitalizing on posi-
tive moments, and anticipating pleasant moments. Sa-
voring an agreeable experience involves becoming aware
of that pleasure or of the positive emotions the partici-
pant is feeling at a given moment [22]. For example, par-
ticipants are invited to look at a picture of pleasant
countryside or listen to soothing music, and to become
aware of the pleasurable experience of doing this and to
appreciate it. Increasing behavioral expression of emo-
tions involves using facial expressions or gestures to ac-
company that positive emotion. The participants are
invited to imitate pictures of actors expressing a positive
emotion and to become aware of the sensations this pro-
duces. Making the most of positive moments entails
communicating and celebrating positive events with
others. For example, participants were invited to de-
scribe positive events to one another through role-play.
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Anticipating pleasant moments involves imagining
the sensations produced by a positive future event.
This strategy is meant to guide the participants
through different positive feelings and emotions. It
can engage their different senses, for example, by im-
agining they are eating a fruit, or by anticipating the
emotion produced and the physical sensations experi-
enced upon the completion of a pleasurable physical
or social activity. A simple homework task is
assigned to be done between each session. For ex-
ample, this could be, choosing an image or an object
that provokes a positive emotion or feeling in the
participant, who must then bring it back and to
present it to the group.
Psychoeducational concept
The psychoeducational concept underpinning the pro-
gram was built according to Kolb & Kolb's model [44] of
experiential learning. Each learning activity involves: 1)
concrete experience, during which the participant com-
pletes a concrete task (e.g. savoring the pleasure of look-
ing at a beautiful landscape); 2) reflective observation,
during which the participant reflects on his/her experi-
ence, his/her past—the participant communicates about
the completion of the task (e.g. sharing what pleasure
was provoked by looking at the landscape and how it
has been savored); 3) abstract conceptualization, during
which the participant interprets events—theoretical links
are created or introduced by a third party (e.g. explain-
ing the importance of savoring in daily life); and 4) ac-
tive experimentation, during which the participant
anticipates a new means of trying out the task, in light
of the skills acquired in the preceding phase, and then
executes them (e.g. experimenting savoring in daily life
and taking note in a journal of the experience of savoring
pleasurable experience). The program uses a collab-
orative, egalitarian approach. Group facilitators par-
ticipate in sessions just like the participants, by doing
the exercises, by sharing their experiences, and by
carrying out the given tasks.
Patients participated in eight one-hour sessions of
PEPS at a rate of one per week.
Session List:
– Session 1: defeatist thinking
– Session 2: savoring pleasant moments (I)
– Session 3: accentuating the behavioral expression of
emotions
– Session 4: making the most of pleasant moments by
sharing them with others
– Session 5: savoring past pleasant moments (II)
– Session 6: anticipating pleasant moments (I)
– Session 7: anticipating pleasant moments (II)
– Session 8: review of all skills.
Participants conduct the reviewing exercises them-
selves during the last session.
Ethical aspects
Protocol 127/14, Pilot Study for the Positive Emotions
Program for Schizophrenia (PEPS), a study for improv-
ing anhedonia, was accepted by the Vaud Cantonal Eth-
ics Commission on Human Research on 6th May 2014.
Participants signed an informed consent to be included.
Data analyses
Results are presented using descriptive statistics and in-
dependent and paired t-tests according to the compari-
sons between or within participants. Effect sizes were
calculated using paired t-tests statistics, using the for-
mula reported by Borenstein and taking into account the
dependence between data points [45]. A Bonferroni cor-
rection was applied for multiple testing.
Results and discussion
Participants’ description
Thirty-nine participants were recruited, two of whom re-
fused to give their consent for the study. The final group
was composed of 24 men and 13 women, with an aver-
age age of 41.84 years old (S.D. = 11.99). Thirty-one met
the criteria for ICD-10 schizophrenia and six met the
criteria for a schizoaffective disorder. Their mean dur-
ation of illness was 19.05 years (S.D. 12.85). Twenty-
eight were single, eight were separated or divorced, and
one was a widower. In terms of the educational level
which they had achieved: six had not finished their
mandatory schooling, 17 participants had finished their
mandatory schooling, three had a secondary school dip-
loma, eight had completed a professional apprenticeship
and three had either a professional school or university
diploma. Three participants lived independently, two
lived with their families, and 32 lived in sheltered hous-
ing. None of the participants had a job on the competi-
tive labor market. All participants except one were on
antipsychotic medication. Fourteen were on antidepres-
sant at mean fluoxetine equivalents of 29.60 mg (SD
14.01) [46]. Figure 1 present the CONSORT flowchart of
the study. Twenty-eight participants completed all eight
sessions, two completed seven sessions, and one partici-
pant in the four cohorts only completed four sessions.
Six participants dropped-out, one refused to participate
after the first assessment, one moved away, and four left
the program before it finished. Two refused to continue
the program, without giving an explanation according to
the informed consent form. However, four provided
reasons for giving up which were unconnected with the
program (external stressors).Table 1 shows that partici-
pants who dropped out did not differ from those who
completed the program. Participants who dropped out
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Figure 1 CONSORT 2010 Flow Diagram
Table 1 Participant descriptions: completers vs drop-outs
Completers Drop-outs Statistics test*; p-value
n = 31 n = 6
Mean (S.D.) N (%) Mean (S.D.) N (%)
Socio-demographic characteristics
Sex female/male 12/19 1/5 Fisher’s exact test; p = .39
Age 42.97 (S.D. 12.33) 36.00 (S.D. 8.67) Mann–Whitney U = 63; p = .23
Professional/university education level 9 (29 %) 2 (33 %) Fisher’s exact test; p =1.00
Home situation: Nursing home 24 (77 %) 5 (83 %) Fisher’s exact test; p = 1.00
ICD-10 diagnosis
Schizophrenia 27 4 Fisher’s exact test; p = .25
Schizoaffective disorders 4 2
Duration of illness since first hospitalization (years) 19.71 (S.D. 12.69) 15.67 (S.D. 14.35) Mann–Whitney U = 76; p = .51
Current treatment
Atypical antipsychotic 24 (80 %) 6 (100 %) Fisher’s exact test; p = .56
Typical antipsychotic 6 -
No antipsychotic 1 -
Antidepressant 13 1 Fisher’s exact test; p = .38
Antidepressant in fluoxetine equivalents 28.45 (13.97) 44.44
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did not differ, either from those who completed PEPS on
the SANS and CDSS at baseline. Participants were re-
cruited between May 20th 2014 and November 30th
2015.
Comparison between pre- and post-tests.
In post-tests, the participants had significantly improved
(reduced) the average total scores for the Avolition-
Apathy and Anhedonia-Asociality scales of the SANS.
They exhibited Cohen's d effect sizes of 0.50 for the
Anhedonia-Asociality scale and 0.57 for the Avolition-
Apathy scale, resulting in a moderate overall effect size.
The average total score for the CDSS also showed a sig-
nificant improvement in the post-test, with a Cohen's d
effect size of 0.91. The affective flattening or blunting,
the alogia and the attention scales of the SANS did not
change during the intervention.
Finally, the average total score on the SANS and
the average total score on the Savoring Belief Inven-
tory showed small effect sizes, but they were not sta-
tistically significant because the Bonferroni correction
needs a p < .001. Table 2 present the pre- and post-
test results (see Table 2).
Secondary analyses
In order to disentangle apathy and anhedonia from de-
pression, our sample was divided into 17 depressed and
14 not depressed participants: those with a CDSS score >
6 were classed as depressed [39, 47]. Depressed and not
depressed participants were compared by using the
pre-post differences in their scores for the SANS
Avolition–Apathy and SANS Anhedonia–Asociality.
Mann–Whitney U tests were 147.0 for the Avolition–
Apathy scale(median difference for depressed partici-
pants = −1.0, semi-interquartile range = −.5; median
difference for non-depressed participants = −1.0, semi-
interquartile range = −1, p = .28) and 65.0 for the Anhedo-
nia–Asociality scale (median difference for depressed par-
ticipants = −3.0, semi-interquartile range = −1.5; median
difference for non-depressed participants = 0.0, semi-
interquartile range = −1, p = .03). The depressed partici-
pants showed more improvement than not depressed
participants. At post-test, only nine of the participants
were still depressed according to the > 6 cut-off point.
Discussion
This initial study demonstrated that the Positive Emo-
tions Program for Schizophrenia (PEPS) is a feasible
treatment method. The preliminary results, presented
here, indicate that PEPS was accompanied by a reduc-
tion of anhedonia, apathy, and depression in a group of
participants diagnosed with schizophrenia or schizoaf-
fective disorders. In addition, the results indicate that
PEPS may have a potential specific effect on the reduced
experience negative symptoms compared to the reduced
expression negative symptoms. These results are encour-
aging and suggest the need for a randomized trial. Fur-
thermore, the scientific results were corroborated by the
patients’ enthusiasm and diligent participation, some-
thing that is not customary for this population. All the
patients expressed a very positive opinion about the
intervention. Nevertheless, a few participants (six) did
drop out of the study (a rate of 16 %). However, a 16 %
drop-out rate is only slightly higher than the average
13 % drop-out rate found in randomized clinical trials of
psychosocial treatments [48]. It should be noted that the
present sample corresponds to a population with a ra-
ther severe disability: their mean duration of illness was
19.05 years. Several participants spontaneously declared
their appreciation of the fact that the group leaders also
participated in the exercises, sharing their personal expe-
riences and even carrying out the homework tasks. A
few participants even stated that the very fact that some
group leaders reported experiencing less pleasure in cer-
tain exercises than the patients did themselves, demon-
strated to them that pleasure might be independent of
their illness. Thus the collaborative approach alone, used
Table 2 Pre and post intervention differences
Pre-test Mean(sd) Post-test Mean(sd) t (df); p Cohen s’d
SANS scale scores
Affective flattening or blunting 9.74 (7.43) 9.45 (5.93) t = .24 (30); p = .82 0.04
Alogia 4.58 (2.87) 4.35 (2.22) t = .59 (30); p = .56 0.08
Avolition – Apathy* 6.29 (3.82) 4.29 (2.76) t = 3.84 (30); p = .001 0.57
Anhedonia – Asociality* 11.10 (3.90) 9.26 (3.26) t = 3.81 (30); p = .001 0.50
Attention 3.42 (2.38) 2.87 (2.73) t = 1.10 (30); p = .28 0.21
SANS-total score 35.13 (13.70) 30.23 (12.25) t = 2.48 (30); p = .02 0.38
CDSS total score* 8.39 (4.58) 4.55 (3.72) t = 4.61 (30); p = .000 0.91
Savoring Belief Inventory total score 4.52 (7.81) 7.81 (8.67) t = −2.26 (30); p = .03 0.34
*p < .005, Boneferroni correction for multiple tests (8 comparisons)
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as a part of the program’s psychoeducational format,
may have had an impact on participants.
These results are consistent with those of two other
pilot studies using ingredients of positive psychology
that target positive emotions in people with schizophre-
nia [31, 49].
This study has several limitations. Firstly, since there
was no control group, the psychologist who assessed the
participants was not blind. The absence of a control
group does not control for the attention given to the
participants. A novelty effect is possible according to the
enthusiasm of the participants who advertise to invite
other patients to come to the program. Depression
scores also showed improvement, and it can be difficult
to distinguish depression from apathy and anhedonia.
The depressed participants showed more improvement
than not depressed participants, suggesting that anhedo-
nia and depression are closely tied together. Further
studies using PEPS should continue to explore these
differential impacts in order to better distinguish de-
pression from the anhedonia negative symptom in
schizophrenia. Change in the Avolition–Apathy score
appears to be less associated with a patient’s depression
status. Since it is estimated that comorbid depression oc-
curs in 50 % of patients with schizophrenia [50], this dis-
tinction is more conjectural than realistic. Interventions
which successfully reduce depression and negative symp-
toms are, nevertheless, highly sought after. In further stud-
ies, it would also be interesting to examine if PEPS
influence psychotic symptoms.
Conclusions
PEPS aims at challenging defeatist thoughts and teaching
new skills to anticipate and maintain positive emotions.
This pilot study with PEPS was associated with a reduc-
tion in depression, apathy, and anhedonia. Affective flat-
tening and alogia remain stable during the intervention,
suggesting a potential specific effect of PEPS on anhedo-
nia and apathy. These favorable results should be now
studied further using a randomized trial.
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